Fate Therapeutics reports lower Q4 collaboration revenue

Fate Therapeutics

26/02/2026 14:09

Overview

Biopharmaceutical firm's Q4 collaboration revenue fell yr/yr

Company reported Q4 net loss of $32.4 mln

Operating expenses decreased 30% in 2025 compared to 2024

Outlook

Company projects operating runway through year-end 2027 with $205 mln in cash

Fate Therapeutics to provide clinical updates in H2 2026

Company plans Phase 2 trial in lupus nephritis

Result Drivers

OUTPATIENT TREATMENT - FT819 off-the-shelf CAR T-cell therapy enabled outpatient treatment, expanding access and reducing hospital stays

CANCER THERAPY SUCCESS - FT836 showed significant tumor reduction in colorectal cancer without conditioning chemotherapy, highlighting early activity

COST REDUCTION - Company plans a 30% reduction in operating expenses in 2025 compared to 2024, supporting financial runway through 2027

Company press release: ID:nGNX5WTXcW

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Collaboration Revenue
$1.37 mln
Q4 Net Income
-$32.37 mln
Q4 Basic EPS
-$0.27
Q4 Income from Operations
-$34.72 mln
Q4 Operating Expenses
$36.09 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Fate Therapeutics Inc is $5.00, about 237.8% above its February 25 closing price of $1.48

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)